We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register to chat with like-minded investors on our interactive forums.
| Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
|---|---|---|---|---|---|
| Afriag | LSE:AFRI | London | Ordinary Share | IM00B3VVCM89 | ORD 0.1P |
| Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| 0.00 | 0.00% | 0.085 | 0.00 | 01:00:00 |
| Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
|---|---|---|---|---|---|
| 0 | 0 | N/A | 0 |
From May 2019 to May 2024
15 July 2019
AfriAg Global PLC
(‘AfriAg’ or the ‘Company’)
Completion of First Two investments in Apollon Formularies Ltd
AfriAg Global PLC, a company whose shares are admitted to trading on London’s NEX Exchange, is pleased to announce that it has now closed its £1 million investment into Apollon Formularies Ltd, with this investment representing 2.325% of the Apollon.
For further details on Apollon Formularies Ltd, please refer to previous announcements.
The directors of the Company accept responsibility for the contents of this announcement.
-ENDS-
For further information on AfriAg Global please visit the www.afriagglobal.com or please contact;
AfriAg Global Plc:
David Lenigas (Executive Chairman) +44 (0)20 7440 0640
Peterhouse Capital Limited +44 (0)20 7469 0930
Guy Miller/Fungai Ndoro
Copyright y 15 PR Newswire
1 Year Afriag Chart |
1 Month Afriag Chart |
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
